Physician profile
Kurt James Reyes
NPI 1275684094
$4,471.49
in general payments reported to CMS, 2019-2025
23 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Obesity Medicine (Internal Medicine) provider received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $1,427 · 2021: $701 · 2022: $422 · 2023: $331 · 2024: $403 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,371.16 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $542.34 | 2020-2025 | Jardiance, Emgality, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $524.10 | 2019-2024 | Farxiga, Airsupra |
| Kvk-Tech, INC. | $428.72 | 2019-2024 | |
| Pfizer INC. | $227.67 | 2020-2024 | |
| Abbvie INC. | $207.49 | 2020-2025 | |
| Genentech USA, INC. | $168.39 | 2019-2020 | |
| Amarin Pharma, INC. | $159.76 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.06 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $122.74 | 2020-2022 | |
| Almatica Pharma LLC | $104.75 | 2023-2025 | Loreev Xr, Gralise |
| Idorsia Pharmaceuticals US INC | $100.83 | 2022-2025 | Quviviq, Quviviq |
| Vivus LLC | $59.21 | 2019-2021 | |
| Corcept Therapeutics | $55.69 | 2025 | Korlym |
| Abbott Laboratories | $54.54 | 2024-2025 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.43 | 2023-2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $41.22 | 2020-2021 | |
| Esperion Therapeutics, INC. | $32.71 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.94 | 2025 | |
| Wright Medical Technology, INC. | $15.31 | 2020 | |
| Allergan, INC. | $14.92 | 2020 | |
| Eisai INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.